Advertisement
Advertisement
U.S. Markets open in 9 hrs 27 mins
Advertisement
Advertisement
Advertisement
Advertisement

Global Wellness Strategies Inc. (O3X.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.1170-0.0020 (-1.68%)
At close: 08:05AM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1190
Open0.1170
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's Range0.1170 - 0.1170
52 Week Range0.0060 - 0.2320
Volume10,000
Avg. Volume1,057
Market Cap2.762M
Beta (5Y Monthly)-1.48
PE Ratio (TTM)N/A
EPS (TTM)-0.0690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Global Wellness Strategies Forms Pharma Subsidiary Focused on Clinical Trials

    Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X) (OTCQB: GWSFF) ("Global" or the "Company") a prospect generator that provides high growth companies with financial, operational, and management assistance focused in health and wellness announces the formation of a wholly owned pharma subsidiary focused on clinical trials."Real strategic capital market partnerships are essential to assist our clients in their progression to t

  • Newsfile

    Global Wellness Corporate Quarter Highlights

    Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X4) (OTCQB: GWSFF) ("Global" or the "Company") provides quarter corporate highlights.The Company quarter corporate highlights included announcing:May 12th that Global Wellness' Shanti Therapeutics was preparing for their first clinical trial with iNGENü a subsidiary of Australian leader Cannvalate. Shanti' s product suite of MDMA could be the global market winner finding a solution

  • Newsfile

    Global Wellness Readies for First Clinical Trial

    Shanti's Focus on Chronic Pain Market with Psychedelics Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (OTCQB: GWSFF) (FSE: O3X) ("Global" or the "Company") announces Shanti Therapeutics MDMA Clinical Trial Update.Shanti's product suite of MDMA could be the global market winner finding a solution to the chronic puzzle of pain. iNGENü, a subsidiary of Australian leader Cannvalate, is engaged as the CRO (clinical research organization) by

Advertisement
Advertisement